


PHARMACEUTICAL 2023

LANNETT CO INC Rank 365 of 446









PHARMACEUTICAL 2023

LANNETT CO INC Rank 365 of 446



The relative strengths and weaknesses of LANNETT CO INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LANNETT CO INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 45% points. The greatest weakness of LANNETT CO INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 192% points.

The company's Economic Capital Ratio, given in the ranking table, is -109%, being 152% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	290,116
Cost of Goods Sold	0
Intangible Assets	32,179
Liabilities, Current	104,940
Liabilities, Non-Current	630,558
Other Assets	28,962
Other Compr. Net Income	137
Other Expenses	411,163
Other Liabilities	0
Other Net Income	-57,651
Other Revenues	340,579
Property and Equipment	133,178
Research and Development	22,362
Selling, General and Administrative Expense	81,023

Output Variable	Value in 1000 USD
Assets	484,435
Liabilities	735,498
Expenses	514,548
Revenues	340,579
Stockholders Equity	-251,063
Net Income	-231,620
Comprehensive Net Income	-231,552
Economic Capital Ratio	-109%

